Non-inferiority of DTaP-IPV co-administered with MMR-RIT compared to co-administration with MMR II in terms of antibody concentrations or titers against polio and pertussis antigens was demonstrated, as the lower limit of the 97.5% CIs of the adjusted GMC/GMT ratios (MMR-RIT over MMR II) was ≥0.67 for anti-PT, anti-FHA, anti-PRN antibodies and for antibodies against the 3 poliovirus (PV) strains (Table 5). The gene discussed is F2; the disease is poliomyelitis.